Author

A. S. Godoy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1 Assay:structural biology· 1 Organism:virus· 1

Frequent Co-Authors

A. C. Puhl· 2 shared G. Oliva· 2 shared R. S. Fernandes· 2 shared S. Ekins· 2 shared D. H. Foil· 1 shared E. S. Silva· 1 shared G. D. Noske· 1 shared G. Olivia· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. C. Puhl

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Structural basis of nirmatrelvir and ensitrelvir resistance profiles against SARS-CoV-2 Main Protease naturally occurring polymorphisms

G. D. Noske, E. S. Silva, M. O. Godoy, I. Dolci, R. S. Fernandes, R. V. C. Guido, P. Sjo, G. Oliva, A. S. Godoy

The paper characterizes natural polymorphisms in SARS-CoV-2 main protease and their resistance profiles against nirmatrelvir and ensitrelvir, revealing structural bases for resistance.

bioRxiv · Aug 31, 2022 · PreprintBiochemistry

Discovery of a Novel Inhibitor for Chikungunya Virus

A. C. Puhl, R. S. Fernandes, A. S. Godoy, L. H. V. G. Gil, G. Oliva, S. Ekins

This study identifies 3-methyltoxoflavin as an inhibitor of Chikungunya virus with EC50 200 nM and activity against yellow fever virus.

bioRxiv · Mar 23, 2022 · PreprintMicrobiology

Machine Learning Models Identify Inhibitors of SARS-CoV-2

V. O. Gawriljuk, P. P. Kyaw Zin, D. H. Foil, J. Bernatchez, S. Beck, N. Beutler, J. Ricketts, L. Yang, T. Rogers, A. C. Puhl, K. M. Zorn, T. R. Lane, A. S. Godoy, G. Olivia, J. L. Siqueira-Neto, , S. Ekins

The paper uses machine learning to predict SARS-CoV-2 inhibitors from FDA-approved compounds, identifying CPI1062 and CPI1155 as potential antiviral drugs.

bioRxiv · Jun 16, 2020Pharmacology & Toxicology